NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Emergent BioSolutions Inc. (EBS) Stock Analysis

Emergent BioSolutions Inc. (EBS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

EBS

$6.21

−$0.02 (−0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EBS with… →

EBS Key Statistics

As of Sep 4, 2026
Trading
Open
$6.26
Previous Close
$6.23
Day's Range
6.14–6.30
52-Week Range
4.36–14.06
Volume
998.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.34
Valuation
Market Cap
$318.41M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.93
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.38
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.40
Financials (FY)
Revenue (FY)
$705.20M−30.43%
Net Income (FY)
$52.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
−22.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.27M
1-Year Return
−18.61%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
1.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EBS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.76%
2025+29.29%
2024+298.33%
2023−79.68%
2022−72.83%
2021−51.48%
2020+66.08%
2019−8.99%
2018+27.57%
2017+41.50%
2016 (partial year)+10.31%

As of September 4, 2026.

EBS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$705.20M$52.60M7.5%
2024$1.01B−$190.60M−18.8%
2023$1.02B−$760.50M−74.3%
2022$1.08B−$211.60M−19.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$705.20M$379.00M$112.30M$52.60M7.5%
2024$1.01B$332.30M−$81.50M−$190.60M−18.8%
2023$1.02B$317.60M−$201.50M−$760.50M−74.3%
2022$1.08B$383.00M−$163.30M−$211.60M−19.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EBS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricEBSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.412.300.2x the median
Profit margin−22.96%−3.14%19.8 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Emergent BioSolutions Inc. (EBS) carries a market capitalisation of $318.41M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 900 employees.

Over the past 52 weeks the price has ranged from $4.36 to $14.06. EBS last closed at $6.21 on September 4, 2026. That is −$0.02 (−0.32%) against the previous close. The latest close sits 42.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $705.20M. Against the prior fiscal year total of $1.01B, that is a change of −30.43%. Net income for the same year was $52.60M. Profit margin runs at −22.96%. That is 19.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −3.4.

Across the 4 fiscal years on file, revenue moves from $1.08B in 2022 to $705.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 5.93. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.38. The price-to-sales ratio is 0.41. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −18.61%. Across 10 years the annualized return works out at −13.64%. The reported beta is 2.34. Daily returns over the trailing 10 years annualize to a volatility of 80.49%.

Growth & Income

No dividend is on file for EBS.

2026 is still running; the price is −49.76% year to date. The strongest complete calendar year on file is 2024 at +298.33%; the weakest is 2023 at −79.68%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Emergent BioSolutions Inc. (EBS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Emergent BioSolutions Inc. EBS $318.41M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Emergent BioSolutions Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Visit website →